Myeloperoxidase and eosinophil peroxidase granules zurophilic proteins are a marker important in asthma patients. In the current study myeloperoxidase (MPO) and Eosinophil peroxidase levels were assessed in different stages of asthma, in 100 patients suffering from asthma, classified as (active asthma, moderate, and severe) according to diagnosis by specialist physician In addition to 20 healthy controls. Results of the current study showed mean serum level of MPO was 16.37 ± 7.78 ng/ml (median ± SD) in controls, and 39.80 ± 22.22 ng/ml in the asthma patients. According to the asthma severity MPO levels were (40.54 ± 29.92, 36.91 ± 20.18 and 34.42 ± 16.04 ng/ml) (median ± SD) in (active asthma, moderate, and severe) asthmatics patients, respectively with significant differences (P ≤ 0.05) between all type of asthma patients and healthy controls, according to asthma severity the results showed significant differences (P ≤ 0.05) between the type of asthma patients active asthma and severe asthmatics. On the other hand eosinophil peroxidase levels of EPO were 47.68 ± 5.78 ng/ml (median ± SD) in control and 75.89 ± 14.46 ng/ml in the asthmatic patients. Depending on the asthma severity, the EPO levels were 76.81 ± 11.45 ng/ml, 68.05 ± 11.29 ng/ml, 66.19 ± 11.77 ng/ml in active asthma, moderate, and severe asthmatics respectively, the results show no significant differences between the type of asthma patients (P ≥ 0.05), but show significant differences between the type of asthma patients and healthy controls and significant differences active asthma and severe asthmatics between 76.81 ± 11.45, 66.19 ± 11.77 ng/ml respectively. Results of the study showed elevated levels of both enzymatic (EPO and MPO) respectively in asthma patients with active asthma with high significant different (P ≤ 0.01) compared with controls, while the results showed serum levels of EPO higher than MPO in patients.